CTOs on the Move

PMV Pharmaceutcals

www.pmvpharma.com

 
PMV is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Shibu Sleeba
 Vice President, Information Technology Profile

Funding

PMV Pharmaceutcals raised $104M on 02/23/2017
PMV Pharmaceutcals raised $74M on 02/23/2017
PMV Pharmaceutcals raised $62M on 11/13/2019
PMV Pharmaceutcals raised $70M on 08/03/2020

Similar Companies

STI Technologies

STI Technologies Limited (STI) is a health-care technology company that provides Canadian patients with greater choice and broader access to the best medications and health care products.

Greenrise Global Brands

Greenrise is a Canadian publicly traded corporation with its representative office located in Hamburg, Germany and operates in the medical and CBD cannabis markets in Germany.

Breckenridge Pharmaceutical

Breckenridge Pharmaceutical Inc. is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthEconomics.Com

HealthEconomics.Com is the worlds most comprehensive and credible website for resources and jobs in healthcare value and market access.

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.